Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole Dosing in Refractory Reflux Esophagitis
NCT01669811Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in reflux esophagitis (2 arms), sponsored by AstraZeneca. Primary endpoint: Percentage of Participants With Healing of Reflux Esophagitis at 8 weeks. Started Aug 2012; status: completed.
02
Drugs
esomeprazole
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT01669811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01669811.